Q4 2024 Bioharvest Sciences Inc Earnings Call Transcript
Key Points
- BioHarvest Sciences Inc (BHST) achieved a strong revenue growth of 99% for the full year 2024, reaching $25.2 million.
- The company successfully listed on the NASDAQ, enhancing its credibility and market reach.
- Vinnea, the flagship product, has over 50,000 active subscribers and maintains a high subscription revenue rate.
- Gross margins improved significantly, increasing by 1,000 basis points year-over-year to 55% in 2024.
- The company has developed a robust infrastructure for its CDMO division, signing multiple contracts, including a notable partnership with Tate and Lyle.
- Net losses for the fourth quarter of 2024 totaled $3 million, indicating ongoing financial challenges.
- Cash and cash equivalents decreased to $2.4 million as of December 31, 2024, from $5.4 million the previous year.
- Operating expenses increased due to higher marketing spend and CDMO service division costs.
- The company faces potential risks and uncertainties related to its forward-looking statements and industry prospects.
- There is a dependency on the successful commercialization of new products and compounds, which involves regulatory and clinical trial challenges.
Greetings and welcome to the Bioharvest Science's fourth quarter 2024 corporate update conference call. (Operator Instructions) As a reminder, this conference is being recorded.
Before we begin the formal presentation, I'd like to remind everyone that the statements made on today's call and webcast, including those regarding future financial results and industry prospects, are forward-looking and may be subject to a number of risks and uncertainties that could cause potential cause actual results to differ materially from those described on the call. Please refer to the company's regulatory filings for a list of associated risks, and we would also refer you to the company's website for more supporting industry information.
In addition, throughout today's call, the company may refer to adjusted EIA, a non-IFRS financial measure which it believes provides helpful information to investors about the performance of the business on an ongoing basis. A reconciliation of adjusted EIDA to its most directly comparable IFRS financial measure is included in today's earnings release, which is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
